Browse Category

Stock Market News 4 November 2025 - 5 November 2025

NVIDIA’s $4 Trillion AI Revolution: How the Chipmaker Overtook Apple and Microsoft

Nvidia Just Hit $5 Trillion—But Can AMD or Intel Finally Crack Its AI Chip Moat?

The state of play: Nvidia’s grip on AI compute Nvidia’s AI accelerators built on Hopper (H100/H200) and now Blackwell (GB200/B200) remain the default choice for training and serving the largest AI models because they pair raw throughput with a full‑stack
Elon Musk Smashes Records by Hitting $500 Billion Net Worth—How He Got There and What It Means

Elon Musk’s $1 Trillion Tesla Payday on the Line: Norway’s $2T Wealth Fund Says ‘No’ as Shareholders Vote — What It Means for TSLA

The vote that could reshape Tesla — and Musk’s control Tesla’s annual meeting on Thursday, Nov. 6 will decide whether to award Elon Musk a new, decade‑long performance plan that Tesla calls the largest incentive package in corporate history. The
5 November 2025
Nebius (NBIS) Stock Rockets 350% on AI Boom – Bubble or Breakout? Experts Weigh In

‘Vineland ramp’ or bust? Nebius’ Q3 countdown, Microsoft mega‑deal and stock‑split buzz — what investors need to know now

The big picture Nebius — the Amsterdam‑based AI‑infrastructure company created from Yandex’s non‑Russian assets — has become one of 2025’s most closely watched “neocloud” names. Its Nov. 11 Q3 print arrives amid a volatile week for the stock, but also
Carl’s Jr. Drops $1 Meals Across SoCal as Shutdown Breaks Record—Who Qualifies, Where to Go, and What It Means for Fast‑Food Stocks

Carl’s Jr. Drops $1 Meals Across SoCal as Shutdown Breaks Record—Who Qualifies, Where to Go, and What It Means for Fast‑Food Stocks

Key facts (updated Nov. 5, 2025): What’s happening With Washington’s budget impasse stretching to Day 36, the federal shutdown has officially broken the U.S. record. Negotiations sputtered again overnight, as senators floated outlines of a deal but failed to advance
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk’s Weight-Loss Drug Boom Hits a Wall – Wegovy Slowdown Sparks Stock Slump and Forecast Cut

Once Sky-High Valuation Falters Amid Weight-Loss Drug Headwinds Just a year ago, Novo Nordisk – buoyed by the meteoric success of its weight-loss injection Wegovy – briefly eclipsed all other European companies in market value reuters.com. The Danish pharmaceutical giant
1 757 758 759 760 761 928
Go toTop